EGFR and neoplasm: EGR1 high expression correlates with resistance to anti-EGFR treatment in metastatic colorectal cancer patients treated with cetuximab, and silencing EGR1 expression promotes killing HCT116 colorectal cancer cells and delaying tumor growth [31, 32].